Novo Nordisk (NVO)
(Delayed Data from NYSE)
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Q4 Earnings Scorecard and Analyst Reports for Sony, Mondelez & Twilio
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance
by Zacks Equity Research
Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
Top Research Reports for Facebook, Novo Nordisk & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY).
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease
by Zacks Equity Research
If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
by Zacks Equity Research
Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Top Analyst Reports for Alphabet, Comcast & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Comcast (CMCSA) and Accenture (ACN).
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study
by Zacks Equity Research
Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.
The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, QUALCOMM, Novo Nordisk, Boeing and Delta Air Lines
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
by Zacks Equity Research
Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.
Top Research Reports for Alibaba, QUALCOMM & Novo Nordisk
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), QUALCOMM Incorporated (QCOM) and Novo Nordisk AS (NVO).
FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda
by Zacks Equity Research
Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure
by Zacks Equity Research
AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.
Is Novo Nordisk (NVO) a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
by Zacks Equity Research
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors
Top Research Reports for Facebook, Verizon & Toyota Motor
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Toyota Motor (TM).